导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.46% | 1628/4773 |
| 近一周 | 0.74% | 91/5462 |
| 近一月 | 5.51% | 70/5421 |
| 近一季 | 5.14% | 289/5209 |
| 近半年 | 6.01% | 723/4920 |
| 近一年 | 3.21% | 1971/4366 |
| 近两年 | 35.55% | 2072/2954 |
| 近三年 | 43.58% | 645/2253 |
| 成立以来 | 52.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.76% 2896/4961 |
-7.89% 3812/5312 |
- - |
- - |
| 2025 | 9.88% 2848/4813 |
2.35% 1401/3635 |
11.15% 212/4076 |
-8.34% 4030/4524 |
5.39% 448/4813 |
| 2024 | 35.22% 60/3463 |
9.85% 108/2808 |
6.47% 162/3014 |
12.02% 2427/3129 |
3.21% 853/3463 |
| 2023 | -0.75% 470/2656 |
-2.73% 2045/2280 |
4.08% 89/2385 |
4.60% 147/2515 |
-6.27% 1698/2655 |
| 2022 | -4.69% 103/2207 |
2.13% 78/1919 |
-1.52% 1737/2016 |
-8.17% 176/2113 |
3.20% 752/2208 |
| 2021 | 1.86% 652/1822 |
10.36% 41/1255 |
-1.39% 1165/1330 |
-6.00% 890/1466 |
-0.44% 1239/1822 |
| 2020 | 5.06% 886/1250 |
-13.84% 943/1028 |
2.57% 966/1067 |
8.13% 731/1164 |
6.73% 747/1184 |
| 2019 | 25.20% 605/1092 |
15.34% 686/754 |
2.43% 82/804 |
-0.67% 606/850 |
6.69% 572/918 |
| 2018 | -11.53% 76/834 |
- - |
- - |
- - |
-9.07% 121/691 |
| 2017 | 16.13% 240/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.50% 132/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华安中证银行ETF联接A VS. 长安沪深300非周期A(740101) |